Exscientia to screen nearly every known approved and investigational drug - 15,000 clinical molecules - against key COVID-19 drug targets to progress rapid treatments and generate data to seed design of superior molecules 

Exscientia announces joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research 

Coverage of our company in Financial Times newspaper

Financial Times : 

Read the article detailing Exscientia's work on the first AI-designed drug 
to enter clinical trials.

Sumitomo Dainippon Pharma and Exscientia Joint Development  New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial

Exscientia appoints Dr. David Hallett as Chief Operating Officer

Exscientia appoints Dr. David Hallett as Chief Operating Officer as company positions for further growth

AI Design of new therapeutics for cardiovascular and oncology disease

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery

AI Design enables new bispecific small molecule modality

Sanofi Exercises option on Exscientia-designed bispecific small molecule for treatment of immunological conditions

Joint venture will initiate drug discovery programs targeting rare diseases using AI

Exscientia enters broad rare disease drug discovery collaboration with Rallybio

Firm enters a multi-target AI drug discovery partnership with initial focus on oncology

Exscientia expands international collaborations with Shanghai-headquartered GT Apeiron Therapeutics

Exscientia achieves molecule discovery milestone as part of GSK collaboration 

Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia

Exscientia がアジアの創薬マーケットを狙った子会社を日本に設立

Celgene and Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity

Exscientia hires director of data engineering to scale up its AI drug discovery platform

Exscientia to receive up to CHF 67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche

Exscientia initiates sixth AI drug discovery partnership

NEW INVESTORS CELGENE CORPORATION AND GT HEALTHCARE CAPITAL PARTNERS JOIN SERIES A INVESTOR EVOTEC.

Exscientia raises US $26 million in series B financing round to accelerate scaling as the leading AI drug discovery company

Exscientia builds "full stack" AI-driven drug discovery capabilities through acquisition of kinetic discovery

Facilities in the Schrödinger Building to bring together AI experts and biologists

Leading AI-driven drug discovery company Exscientia expands to the Oxford Science Park

Exscientia appoints Georgy Egerov as chief financial officer bringing significant capital markets and strategic development expertise to support business growth

Exscientia to present at Numis T500 conference 2018 - linking innovative companies with investors

Publication including Exscientia's chief chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia appoints Alex Snow, founder of Oxford innovation sciences and former CEO of Lansdowne Partners, as deputy chairman

Exscientia opens new office in Oxford as part of plan for rapid growth and expansion

Exscientia wins science and technology business of the year

Exscientia wins best emerging biotech company award at OBN Annual Awards 2017

Evotec invests in Exscientia to advance AI-driven drug discovery

GSKが指定する最大10の創薬標的タンパク質に絞った前臨床創薬共同研究

EXSCIENTIAはGSKと戦略的共同研究契約を締結

Pre-clinical collaboration focused on up to 10 targets nominated by GSK

Exscientia enters strategic drug discovery collaboration with GSK

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is delighted to announce that its Chief Executive Officer Andrew Hopkins has been named Chemistry World ‘Entrepreneur of the Year’. Chief Technology Officer Jérémy Besnard also won the ‘Rising Star in Industry’ Award at the Chemistry Means Business 2017 Awards, hosted by the UK Royal Society of Chemistry in Manchester this week.

Exscientia wins two awards at Royal Society of Chemistry's 'Chemistry Means Business' Awards 2017

Initiates collaboration to develop bispecific-small-molecule drugs

Exscientia announces EUR250 million collaboration for a multiple-product development and licence option agreement with Sanofi

二重特異性低分子薬剤の共同研究開発を開始

エクセンシアが複数製品開発およびライセンスオプション契約で サノフィとの2億5000万ユーロの提携を発表

Exscientia announces progress in immuno-oncology collaboration with Evotec presented at AACR

Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics

Exscientia names young business of the year

Exscientia one of three finalists for best emerging UK biotech company at the OBN Awards

Exscientia Ltd, reaches first delivery milestone in collaboration with Sumitomo Dainippon Pharma Co., Ltd.

Exscientia CEO Andrew Hopkins wins prestigious BBSRC innovator award

Andrew Hopkins, CEO of Exscientia, is awarded Scottish Enterprise Life Science Business prize

Exscientia partners with Sunovion Pharmaceuticals inc. to research new medicines for psychiatric disorders.

Recruitment of Andy Bell, co-inventor of Sildenafil, to head up Exscientia chemistry team

Bispecific drug discovery agreement with Sumitomo Dainippon Pharma Co., Ltd

BBSRC chief executive Douglas Kell highlights Exscientia approach for advancement of complex drug design

Exscientia strengthens drug design capability with key appointments

Exscientia establishes collaboration with Janssen research & development

Bi-specific enzyme inhibitors deal with top 10 US pharma

Exscientia signs proof-of-concept deal with Sunovion Inc. to discover 'bi-specific' compounts for psychiatric disease

Exscientia have entered into pharma collaborations and co-development projects with industry leaders such as Sanofi, Sunovion, GSK and more. Visit our website today.

Our Projects | Pharma Collaborations | Exscientia

Exscientia’s Centaur Chemist™ Artificial Intelligence-powered platform has been validated by some of the world’s leading pharma companies and has the potential to initiate up to 20 projects per year. Since our foundation in 2012, we have entered into nine pharma collaborations and co-development projects, details of which you can find below. We are also developing our own pipeline projects to help get the right drugs to the right patients faster.

Left

VeryDarkGrey

Large

Drug Discovery in cardiovascular and oncology disease

Starting 2020, Exscientia announced a collaboration focused on the application of artificial Intelligence (AI)-driven drug discovery  with Bayer AG to accelerate small molecule discovery focused on cardiovascular disease and oncology

Accelerating the discovery of small molecule therapeutic drug candidates in oncology and autoimmunity.

In March 2019, Exscientia entered a three-year partnership with Celgene to use AI to accelerate the discovery of small molecule therapeutic drug candidates for three therapeutic programmes for Celgene in the areas of oncology and autoimmunity. Exscientia will apply its full-stack AI drug discovery capabilities to the execution of the entire project – from gene to the drug candidate. This is one of the largest AI drug discovery collaborations to date.

Designing bispecific small molecules for metabolic disease.

In May 2017, Exscientia signed a strategic research collaboration and licence option agreement with Sanofi in the high-interest area of metabolic disease. Exscientia committed to identify and validate combinations of drug targets that could work synergistically and be amenable to our powerful bispecific small molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.  Exscientia is responsible for all compound design, whilst chemistry synthesis will be delivered by Sanofi.  

In July 2019, we announced that Sanofi would exercise their option for an Exscientia-invented bispecific small molecule to treat immunological diseases through two unrelated targets. 

Delivering advanced molecules to accelerate central nervous system drug discovery.

In September 2014, Exscientia entered a partnership with Sumitomo Dainippon Pharma with a focus on Central Nervous System drug discovery. The goal of this partnership was to deliver novel multi-target small molecules that fulfilled demanding selectivity and development criteria and had potential to deliver enhanced therapeutic performance in the treatment of psychiatric diseases.  

Just 12 months later, Exscientia announced the delivery of its first advanced molecule to meet these criteria - five year less than it would have taken using traditional methods. Thanks to Exscientia’s approach, fewer than 400 compounds needed to be synthesised to identify molecules that matched the required development criteria. Following this, two more pre-clinical drug candidates were delivered in the following two years.

Discovering and optimising novel medicines for psychiatric disorders.

In November 2014, Exscientia partnered with Sunovion Pharmaceuticals Inc., to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders. The partnership combined the power of advanced, large-scale phenotypic screening with Exscientia’s AI platform for the rational design of polypharmacology drugs. It built upon Exscientia’s delivery of novel bispecific compounds that combine activities at the GPCR and ion channel target families.

Uncovering novel and selective small molecules for up to ten disease-related targets.

In July 2017, Exscientia entered a collaboration with GlaxoSmithKline to combine its AI platform with the expertise of GSK’s team to discover novel and selective small molecules for up to ten disease-related targets, nominated by GSK across multiple therapeutic areas.   

In April 2019, Exscientia delivered the first major milestone in this collaboration: a highly potent in vivo active lead molecule, targeting a novel pathway for the treatment of chronic obstructive pulmonary disease. The in vivo lead was identified de novo from 85 project compounds and was synthesised and tested within five iterative design and screening cycles - far fewer than conventional industry benchmarks. 

Designing pre-clinical drug candidates in oncology.

In January 2019, Exscientia entered a new collaboration with Roche to apply its AI drug discovery platform to design pre-clinical drug candidates in oncology. 

Discovering and developing first-in-class bispecific small molecule immuno-oncology therapies.

In April 2016, Exscientia announced a research collaboration with Evotec, with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. The initial focus was cancer-related adenosine targets, which are increasingly recognised as playing important roles in immuno-oncology.   

In April 2017, Exscientia presented the results of the collaboration with Evotec to develop adenosinergic small molecules focused on immuno-oncology at the American Association for Cancer Research Annual Meeting in Washington DC.

Fast-tracking the development of novel drugs to tackle high impact therapeutic targets in oncology.

In June 2019, Exscientia entered a partnership with Shanghai-headquartered GT Apeiron Therapeutics. The collaboration will use Exscientia’s full-stack AI drug discovery capabilities and GT Apeiron’s proprietary technologies to accelerate the development of novel drugs via new pathways to tackle high impact therapeutic targets with an initial focus on oncology. As part of the agreement, Exscientia has become a shareholder in GT Apeiron and is entitled to receive milestones and royalties based on the clinical, regulatory and commercial success of each programme.

Developing small molecule drug therapeutics and pre-clinical drug candidates for rare diseases.

In July 2019, Exscientia entered into a collaboration with Rallybio, a seasoned biotech U.S.-based drug development company, which aims to transform lives of patients with rare diseases. The collaboration will combine Exscientia’s AI drug discovery platform with Rallybio’s expertise in rare disease drug development to accelerate the discovery of small molecule drug therapeutics for undisclosed rare disease indications. Exscientia will work with Rallybio’s world-class team of scientists to design pre-clinical drug candidates for their joint venture, RE Ventures.

Our projects in this area modulate the suppressive impact of metabolites in the tumour microenvironment on immune cells.

Reactivating the immune system in the cancer micro-environment is now recognised as a major therapeutic opportunity. 

Our immune system is our body’s defence against infectious organisms and it identifies and eliminates pathogens from our body.  More recent research has demonstrated that our immune system is also responsible for the recognition and elimination of cancer cells.  Unfortunately, cancers evolve mechanisms whereby they can evade or suppress our immune system, allowing the disease to progress. 

Exscientia has developed a portfolio of drug discovery programmes addressing different aspects of the immuno-suppressive tumour microenvironment.

Our portfolio focuses on fast breaking targets that are also small molecule druggable.

Activating our innate immune system to improve the body’s response is currently a focus across multiple therapeutic areas. 

Our innate immune system is our first line of defence against pathogens and in contrast to our adaptive immune system, it provides non-specific mechanisms for recognising foreign or non-self-targets.  Receptors recognising damage associated or pathogen associated molecular patterns can activate the immune system.  This is thought to play a role in diverse diseases such as Alzheimer’s disease and non-alcoholic steatohepatitis.  Inhibition of targets in the innate immune system may resolve the inflammation in such diseases and activation of the innate immune system might be able to increase our body’s capacity to fight cancer.    

Our portfolio focuses on some of the most recent target discoveries focusing on anti-inflammatory and anti-fibrotic mechanisms.

Fibrosis, especially NAFLD and NASH, are recognised as a key area of unmet medical need.

Fibrosis is the name given to the biological process of scarring where extracellular proteins are laid down in response to injury or damage. This deposition of connective tissue generates stiffness and can impair the normal tissue function. In healing, the fibrotic process is switched off and the excessive scar tissue can be removed but in diseases such as idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis the fibrotic process continues.  Recent genetic breakthroughs have identified targets which offer the promise to address the process of fibrosis in the liver.  

We use our creative team and cutting-edge AI technology in partnership with world-class life science industry leaders and resources to create a new standard of drug discovery. 

We are always on the lookout for new collaborations that support and help our mission to deliver faster, better treatments for patients all over the world.

Contact us to discuss partnership opportunities.

Scaling

Pharma Collaborations

Bayer

Drug Discovery in cardiovascular and oncology disease

Celgene

Accelerating the discovery of small molecule therapeutic drug candidates in oncology and autoimmunity.

Sanofi

Designing bispecific small molecules for metabolic disease.

Sumitomo Dainippon Pharma

Delivering advanced molecules to accelerate central nervous system drug discovery.

Sunovion

Discovering and optimising novel medicines for psychiatric disorders.

GlaxoSmithKline

Uncovering novel and selective small molecules for up to ten disease-related targets.

Roche

Designing pre-clinical drug candidates in oncology.

Co-development

Evotec

Discovering and developing first-in-class bispecific small molecule immuno-oncology therapies.

GT Apeiron Therapeutics

Fast-tracking the development of novel drugs to tackle high impact therapeutic targets in oncology.

Rallybio

Developing small molecule drug therapeutics and pre-clinical drug candidates for rare diseases.

FRANCHISE PIPELINE

Immuno-oncology

Our projects in this area modulate the suppressive impact of metabolites in the tumour microenvironment on immune cells.

Innate Immunity

Our portfolio focuses on fast breaking targets that are also small molecule druggable.

Fibrosis

Our portfolio focuses on some of the most recent target discoveries focusing on anti-inflammatory and anti-fibrotic mechanisms.

Partner with us